These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

969 related items for PubMed ID: 17483366

  • 1. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
    Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, Ksander BR, Ostrand-Rosenberg S.
    Cancer Res; 2007 May 01; 67(9):4499-506. PubMed ID: 17483366
    [Abstract] [Full Text] [Related]

  • 2. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
    Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-Rosenberg S.
    Cancer Res; 2006 Jan 15; 66(2):1147-54. PubMed ID: 16424052
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R, Ronteltap C, Heuveling M, Debets R, Bolhuis R.
    Gene Ther; 2005 Jan 15; 12(2):140-6. PubMed ID: 15496961
    [Abstract] [Full Text] [Related]

  • 5. Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells.
    Bosch JJ, Iheagwara UK, Reid S, Srivastava MK, Wolf J, Lotem M, Ksander BR, Ostrand-Rosenberg S.
    Cancer Immunol Immunother; 2010 Jan 15; 59(1):103-12. PubMed ID: 19557412
    [Abstract] [Full Text] [Related]

  • 6. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
    Fujisawa Y, Nabekura T, Nakao T, Nakamura Y, Takahashi T, Kawachi Y, Otsuka F, Onodera M.
    Exp Dermatol; 2009 Apr 15; 18(4):396-403. PubMed ID: 19054057
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
    Chen PW, Ksander BR.
    Curr Eye Res; 2006 Jan 15; 31(1):43-55. PubMed ID: 16421019
    [Abstract] [Full Text] [Related]

  • 13. Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma.
    Hsueh EC, Famatiga E, Shu S, Ye X, Morton DL.
    Ann Surg Oncol; 2004 Oct 15; 11(10):892-9. PubMed ID: 15383418
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator.
    Radosevich M, Jager M, Ono SJ.
    Exp Mol Pathol; 2007 Feb 15; 82(1):68-76. PubMed ID: 16650406
    [Abstract] [Full Text] [Related]

  • 15. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope.
    Röhn TA, Reitz A, Paschen A, Nguyen XD, Schadendorf D, Vogt AB, Kropshofer H.
    Cancer Res; 2005 Nov 01; 65(21):10068-78. PubMed ID: 16267033
    [Abstract] [Full Text] [Related]

  • 16. Rapid expansion of tumor-reactive cells from HLA-matched siblings for adoptive immunotherapy of melanoma.
    Gottlieb DJ, Micklethwaite K, Bradstock KF, Li YC.
    Cytotherapy; 2007 Nov 01; 9(2):133-43. PubMed ID: 17453965
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Interferon-gamma regulates the T cell response to precursor nevi and biologically early melanoma.
    Guerry D, Alexander MA, Elder DE, Herlyn MF.
    J Immunol; 1987 Jul 01; 139(1):305-12. PubMed ID: 3108402
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.